[27P-pm] Prevention of drug abuse (medicinal products)/Pharmacoepidemiology, Health economics/Pathophysiology (Pathological models, Cancer)/Others

1:30 PM - 5:00 PM JST(4:30 AM - 8:00 AM UTC)

[27P-pm478S] Cost-Effectiveness study of Pembrolizumab for PD-L1 triple-negative breast cancer based on KEYNOTE-355 trial in Japanese subpopulation

○Takako Komuro¹, Yugo Chisaki¹, Nobuhiko Nakamura¹, Noriaki Kitada¹ (1. Kyoto Pharm. Univ.)

Password required to view

Enter the password to view the abstracts.
The password will be emailed to those who have completed the registration.